New approaches to the treatment of pancreatic cancer: From tumor-directed therapy to immunotherapy Journal Article
| Authors: | Lowery, M. A.; Oreilly, E. M. |
| Article Title: | New approaches to the treatment of pancreatic cancer: From tumor-directed therapy to immunotherapy |
| Abstract: | The development of novel therapeutic strategies for pancreatic adenocarcinoma (PAC) has traditionally been considered particularly challenging for clinical and laboratory investigators due to its aggressive underlying biology and inherent resistance to currently available therapies. More recently, however, advances have been made in the identification of promising therapeutic targets for intervention, along with several key insights into the complex sequence of genetic alterations involved in the evolution of PAC from premalignant precursor lesion to malignant cells with metastatic potential. FOLFIRINOX (5-fluorouracilleucovorinirinotecanoxaliplatin) has recently been identified as a combination cytotoxic therapy associated with a significant survival benefit over single-agent gemcitabine in good performance status patients with advanced disease; it is hoped that a similar benefit will be seen in planned trials of FOLFIRINOX as perioperative therapy. The success of immune therapy with the anti-cytotoxic T-lymphocyte antigen-4 antibody ipilimumab in advanced melanoma has spurred interest in the development of vaccines and immune therapies for other solid tumors. Certainly, the concept of harnessing the power of the immune system for cancer treatment is an attractive concept to patients and clinicians alike. Herein we discuss recent advances in the development of novel therapeutic approaches to PAC, focusing in particular on recent developments in immune and vaccine therapy. © 2011 Adis Data Information BV. All rights reserved. |
| Keywords: | cancer survival; treatment outcome; unclassified drug; gene mutation; overall survival; fatigue; bevacizumab; erlotinib; fluorouracil; cancer combination chemotherapy; diarrhea; drug efficacy; monotherapy; nonhuman; solid tumor; drug targeting; capecitabine; gemcitabine; paclitaxel; pancreas cancer; combined modality therapy; pancreatic neoplasms; adenocarcinoma; ipilimumab; unindexed drug; cancer immunotherapy; melanoma; progression free survival; drug eruption; ovary cancer; breast cancer; antineoplastic combined chemotherapy protocols; peripheral neuropathy; camptothecin; cyclophosphamide; antineoplastic activity; cetuximab; distant metastasis; irinotecan; febrile neutropenia; genome analysis; tumor suppressor gene; drug fatality; antibodies, monoclonal; immunotherapy; cancer vaccine; cancer vaccines; folinic acid; cancer immunization; tyrosine kinase receptor; antiangiogenic therapy; aflibercept; pancreas adenocarcinoma; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; interstitial lung disease; perioperative period; peptide vaccine; axitinib; trastuzumab; granulocyte macrophage colony stimulating factor vaccine; oxaliplatin; deoxycytidine; organoplatinum compounds; leucovorin; lapatinib; drug formulation; olaparib; cancer antibody; pancreatic-cancer; randomized controlled trial (topic); clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); iniparib; multicenter study (topic); anti-ctla-4-monoclonal-antibody; cancer-vaccines; immunotherapies; poly(adp-ribose)-polymerase-inhibitors; receptor-protein- tyrosine-kinase-antagonists; ganitumab; prostate stem cell antigen antibody; telovac; tertomotide; veliparib; vismodegib |
| Journal Title: | BioDrugs |
| Volume: | 25 |
| Issue: | 4 |
| ISSN: | 1173-8804 |
| Publisher: | Adis Data Information Bv |
| Date Published: | 2011-08-01 |
| Start Page: | 207 |
| End Page: | 216 |
| Language: | English |
| DOI: | 10.2165/11592470-000000000-00000 |
| PROVIDER: | scopus |
| PUBMED: | 21815696 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 October 2011" - "CODEN: BIDRF" - "Source: Scopus" |
